Ataiy Omed, Burniki Mia, Sohrabi Keywan, Groß Volker, Scholtes Michael, Schudt Florian
Faculty of Health Sciences, University of Applied Sciences, Giessen, Germany.
Digit Health. 2024 Dec 19;10:20552076241302676. doi: 10.1177/20552076241302676. eCollection 2024 Jan-Dec.
Digital health applications are digital medical products (e.g. apps and web applications) that are prescribed by healthcare service providers and reimbursed by health insurances. Before digital health applications can be prescribed, manufacturers must fulfill the requirements of the approval process. The aim of this study is to identify the challenges faced by digital health applications manufacturers in the German fast-track process.
Use of a questionnaire-based online survey with 10 digital health applications manufacturers from March to October 2023. The survey design is based on the German digital health application regulation and the digital health application guideline. Data collection via LimeSurvey and HubSpot and data visualization in bar charts.
Digital health applications manufacturers see the fast-track process as a challenge, especially in terms of demonstrating positive care effects and compliance with regulatory standards. Challenges include conducting clinical trials, negotiating pricing and improving market acceptance even with innovative approaches. Views on the profitability and relevance of the digital health application model are varied, with concerns over pricing and market strategies predominating.
The fast-track approval of digital health applications in Germany is a significant barrier to innovation and market entry. Collaboration between stakeholders is essential to optimizing processes while ensuring safety and accessibility for patients. However, even with the limitations, the results provide insights for future research and policy refinements that are necessary to improve the implementation of digital health applications in healthcare.
数字健康应用程序是由医疗服务提供商开具处方并由健康保险报销的数字医疗产品(如应用程序和网络应用程序)。在数字健康应用程序能够被开具处方之前,制造商必须满足审批流程的要求。本研究的目的是确定数字健康应用程序制造商在德国快速审批流程中面临的挑战。
于2023年3月至10月对10家数字健康应用程序制造商进行基于问卷调查的在线调查。调查设计基于德国数字健康应用程序法规和数字健康应用程序指南。通过LimeSurvey和HubSpot进行数据收集,并以柱状图进行数据可视化。
数字健康应用程序制造商将快速审批流程视为一项挑战,特别是在证明积极的护理效果和符合监管标准方面。挑战包括进行临床试验、协商定价以及即使采用创新方法也难以提高市场接受度。对数字健康应用程序模式的盈利能力和相关性的看法各不相同,对定价和市场策略的担忧占主导地位。
德国数字健康应用程序的快速审批是创新和进入市场的重大障碍。利益相关者之间的合作对于优化流程至关重要,同时要确保患者的安全和可及性。然而,尽管存在局限性,研究结果为未来研究和政策完善提供了见解,这对于改善数字健康应用程序在医疗保健中的实施是必要的。